Contractor profile
Eli Lilly and Company
FY2022 · complete year · data as of 2026-07-11
No FY2026 activity recorded for this recipient. Showing FY2022, its most recent year with data.
prime recipient of federal awards · UEI UHHVNTY54K68 Source
$2.8B
Obligated
FY2022
2
Funding agencies
100%
From Defense
53%
Non-competed
1
States
100%
In Indiana
1
Industries
In FY2022, Eli Lilly and Company received $2.8B in federal awards from 2 agencies, 100% of it from the Department of Defense, with 100% of the work performed in Indiana. Across FY2021 to FY2022 its recorded total is $4.7B. Computed
Where this money comes from
SourceFUNDING AGENCIES
ELI LILLY AND COMPANY
Defense
$2.8B
Eli Lilly and Company
$2.8B
FY2022 obligated
Where the work lands
SourceIndiana$2.8B
Key takeaways
Computed- Eli Lilly and Company received $2.8B in federal obligations in FY2022, up 44% from $1.9B in FY2021.
- It ranked #33 among federal contractors by contract obligations in FY2022.
- The Department of Defense accounted for 100% of it.
- Of its $2.8B in contract obligations, 53% was non-competed, based on FPDS extent-competed codes.
Obligations by year
Computed$1.9B
FY21
$2.8B
FY22
▲ 44%
since FY21
Awards
SourceLargest active awards by total value
Awards whose period of performance overlaps FY2022, by the amount obligated on each so far.
| Award | ID | Agency | Obligated | Start | End | Place |
|---|---|---|---|---|---|---|
| LYCOV1404 Bebtelovimab | W58P0522C0012 | Department of Defense | $1.5B | 2022-02-10 | 2023-09-30 | Indiana |
| Purchase of a Total of 614,000 Doses of Combination Monoclonal Antibody | W58P0522F0001 | Department of Defense | $1.3B | 2021-11-01 | 2022-02-15 | Indiana |
| Purchase of 388,000 Doses of Monoclonal Antibody LY-COV016 | W58P0521F0002 | Department of Defense | $329.8M | 2021-09-14 | 2021-11-05 | Indiana |
| Combination Monoclonal Antibody - Delivery Order for 100,000 Doses | W911QY21F0167 | Department of Defense | $210M | 2021-02-25 | 2021-11-24 | Indiana |
Largest FY2022 awards
Awards that started in FY2022, by the amount obligated on each so far.
| Award | ID | Agency | Obligated | Start | End | Place |
|---|---|---|---|---|---|---|
| LYCOV1404 Bebtelovimab | W58P0522C0012 | Department of Defense | $1.5B | 2022-02-10 | 2023-09-30 | Indiana |
| Purchase of a Total of 614,000 Doses of Combination Monoclonal Antibody | W58P0522F0001 | Department of Defense | $1.3B | 2021-11-01 | 2022-02-15 | Indiana |
What it does (NAICS / PSC)
Competition
53%non-competed (often called no-bid), of $2.8B in contract obligations in FY2022Computed
This describes how contracts were awarded, not wrongdoing.
Corporate family
Single registration: no combined family.
Related
Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are Source; figures we calculate are Computed; links we infer (corporate parents, districts, similar contractors, connections between records) are Inferred, worded carefully, never asserted as fact and never a claim that one thing caused another. Spot an error? Tell us.